Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
来自 ALUR III 期研究的最终疗效和安全性数据，以及阿来替尼与化疗在克唑替尼预处理的 ALK 阳性非小细胞肺癌患者中的探索性分子谱分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100333
Wolf, J; Helland, Å; Oh, I-J; Migliorino, M R; Dziadziuszko, R; Wrona, A; de Castro, J; Mazieres, J; Griesinger, F; Chlistalla, M; Cardona, A; Ruf, T; Trunzer, K; Smoljanovic, V; Novello, S
